Antineoplastics and Immunomodulators 2026 Tender

• Country: Czech Republic
• Summary: Antineoplastics and Immunomodulators 2026
• CZT Ref No: 133529254
• Deadline: 11 Feb 2026
• Financier: Self Financed
• Purchaser Ownership: Government
• Tender Value: CZK 3872000
• Notice Type: Tender
• Document Ref. No.: 16951-2026
• Purchaser's Detail:
  Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.

  Login to see details
• Description:
• The subject of the public contract is the supply of medicinal products for the therapy of serious chronic diseases in the total expected volume of 85,664 individual doses of medicinal products. The preparations are intended for the provision of health care at medical facilities workplaces of FN Plzeň. Deliveries of the subject of performance will be carried out on the basis of the results of the completed procurement procedure for a period of four years from the signing of the purchase contract. Immunosuppressant containing the active substance tocilizumab Ampoules containing 162 mg of tocilizumab, expected annual volume of 1,160 ampoules (doses); ATC L04AC07 Cytostatic agent containing the active ingredient mosunetuzumab Ampoules containing 30 mg of mosunetuzumab, estimated annual volume of 20 ampoules (doses); ATC L01FX25 Immunosuppressant containing the active substance brodalumab Ampoules with contents 210 mg brodalumab, estimated annual volume of 840 ampoules (doses); ATC L04AC12 Cytostatic agent containing the active substance bevacizumab Ampoules containing 400 mg of bevacizumab, estimated annual volume of 1,600 ampoules (doses); ATC L01FG01 Immunosuppressant with effective content substances dimethyl fumarate P.O. form containing 240 mg of dimethyl fumarate per form unit, estimated annual volume of 15,680 form units (doses); ATC L04AX07 Cytostatic agent containing the active substance ixazomib P.O. a form containing 3 mg of ixazomib per form unit, expected annual volume of 180 form units (doses); after. form containing 4 mg of ixazomib per form unit, estimated annual volume of 36 form units (doses); ATC L01XG03 Cytostatic drug containing the active substance fluoro...
• Documents:

 Tender Notice